Life-Threatening Adenovirus Infections in the Setting of the Immunocompromised Allogeneic Stem Cell Transplant Patients

Table 1

Patient Demographics. Cy/TBI: Cyclophosphamide/Total Body Irradiation, PBSCT: Peripheral Blood Stem Cell Transplant, MUD: Matched unrelated donor, CML: Chronic Myeloid Leukemia, ALL: Acute Lymphocytic Leukemia, CML: Chronic Myeloid Leukemia, M: male, F: female.

	Age/Gender	Disease	Pretransplant Therapy	Conditioning Therapy	Type of Transplant	GVHD Prophylaxis	GVHD Onset	Max Grade GVHD
1	67/M	Follicular Lymphoma	R/CHOP; R/DHAP; Fludarabine	Busulfan Fludarabine TBI	Allogeneic PBSCT	MMF; Cyclosporine	Day +38 Skin, gut Stage II	III
2	44/M	Follicular Lymphoma	R/CHOP; FND-R; Rituxan +; Bortezomib; Genmab Anti-CD20 Ab; Study; R-ICE salvage	Cy/TBI	Sibling Allogeneic PBSCT	Steroids; Methotrexate	Day +20 gut and liver Stage III	IV
3	39/M	CML with T315I mutation	Dasatinib; Imatinib; 3 + 7; HIDAC; 3 + 7	Cy/TBI	MUD PBSCT	Steroids; Methotrexate; Cyclosporine	Day +19 Skin, gut, and conjunctivae Stage IV	IV
4	57/F	Follicular Lymphoma	R/CHOP; RICE; RESHAP; RICE	Cy/TBI	Allogeneic PBSCT	Steroids; Methotrexate; Cyclosporine	Day +30 Gut Stage II	III
5	42/F	ALL	Hyper CVAD	Cy/TBI	MUD	Steroids; Methotrexate; Cyclosporine	Day +360 Skin, gut Stage IV	IV
6	49/M	Multiple Myeloma	Local Radiation; Lenalidomide; Bortezomib/Doxil/Dex	Carmustine Etoposide Cytarabine Mephalan	Allogeneic PBSCT	Steroids; Methotrexate; Cyclosporine	Day +26 gut Stage II	III